Plain-English translation of NCT05626114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called for patients with geographic atrophy, a condition where the central part of the retina (the light-sensing tissue at the back of your eye) gradually breaks down, causing vision loss. consists of special cells that are surgically placed directly under the retina in the back of your eye. The study will evaluate whether this treatment is safe and whether it helps slow or improve vision loss in people with this condition.
Geographic atrophy is a serious form of age-related macular degeneration that currently has limited treatment options, and people's vision can continue to decline over time. This trial exists to see if introducing new cells into the eye might help protect remaining vision or even restore some sight in people living with this condition.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo a surgical procedure in which doctors will inject approximately 200,000 cells under the retina of your eye using specialized surgical techniques. The research team will monitor your safety and measure your vision at multiple visits over time to assess whether the treatment helps preserve or improve your sight. Some participants may also be invited to complete additional imaging tests using a special retinal camera to help researchers better understand how the treatment works.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States